AVROBIO, Inc. (AVRO)
$1.06
Rating:
Recommendation:
-
| Symbol | AVRO |
|---|---|
| Price | $1.06 |
| Beta | 1.555 |
| Volume Avg. | 0.41M |
| Market Cap | 46.318M |
| Shares () | - |
| 52 Week Range | 0.74-6.88 |
| 1y Target Est | - |
| DCF Unlevered | AVRO DCF -> | |
|---|---|---|
| DCF Levered | AVRO LDCF -> | |
| ROE | -67.14% | Strong Sell |
| ROA | -69.61% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 22.48% | Neutral |
| P/E | - | |
| P/B | 0.32 | Neutral |
Latest AVRO news
About
Download (Excel)AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.